Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD)
considering the disease as a continuum. Thanks to evolving biomarker research and …

Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disorder. Impaired
neuronal bioenergetics and neuroinflammation are thought to play key roles in the …

Implementation of amyloid biomarkers in clinical practice would be accelerated if such
biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a …

In the last 20 years, research focused on developing retinal imaging as a source of potential
biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased …

Progress toward the development of efficacious therapies for Alzheimer's disease (AD) is
halted by a lack of understanding early underlying pathological mechanisms. Systems …

The last decade has seen a substantial increase in research focused on the identification of
blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based …

The emergence of complement as an important player in normal brain development and
pathological remodelling has come as a major surprise to most scientists working in …

Background Minimally invasive specific biomarkers of neurodegenerative diseases (NDs)
would facilitate patient selection and disease progression monitoring. We describe the …

The lack of readily available biomarkers is a significant hindrance toward progressing to
effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based …